{
  "nctId": "NCT03767062",
  "briefTitle": "Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches",
  "officialTitle": "Comparison of Effects of Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches: A Randomised Parallel Group Study",
  "protocolDocument": {
    "nctId": "NCT03767062",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-07-07",
    "uploadDate": "2019-12-23T15:45",
    "size": 85853,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03767062/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 90,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-03-01",
    "completionDate": "2019-03-31",
    "primaryCompletionDate": "2019-03-31",
    "firstSubmitDate": "2018-12-05",
    "firstPostDate": "2018-12-06"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Chronic migraine diagnosis according to International Classification of Headache-2 Disorders (ICHD)\n2. w/o pregnancy or breastfeeding.\n3. w/o acute or chronic psychiatric disorders.\n4. w/o nephrolithiasis.\n5. w/o medication of anticoagulant and antiaggregant.\n6. w/o allergy to topiramate or bupivacaine.\n7. w/o prophylaxis within the last three months with any of; propranolol, nebivolol, topiramate, valproate, venlafaxine, duloxetine, amitriptyline, flunarizine.\n8. w/o previous history of peripheral nerve block, botulinum toxin or acupuncture.\n9. w/o history of multiple sclerosis, movement disorders, epilepsy, stroke, and tumor.\n\nJ-w/o chronic systemic diseases including hypertension, cardiac insufficiency, diabetes, pulmonary disease, kidney disease, liver disease, and peripheral arterial disease.\n\nExclusion Criteria:\n\n1. Lost to follow up within the pretreatment period during the detoxification therapy after the detoxification therapy\n2. could not tolerate the peripheral nerve block or topiramate",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "15 Years",
    "stdAges": [
      "CHILD",
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Visual Analog Scale",
        "description": "Range Pain 0-10, 0: No pain, 10: Worst Pain",
        "timeFrame": "Post treatment (4 weeks later)"
      },
      {
        "measure": "Attack Frequencies",
        "description": "Number of headaches patients suffer in a month.",
        "timeFrame": "Post treatment (4 weeks later)"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:54.720Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}